Clovis Oncology, Inc. (CLVS) financial statements (2020 and earlier)

Company profile

Business Address 5500 FLATIRON PARKWAY
BOULDER, CO 80301
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments297520564266529483323
Cash and cash equivalents162222464216279483323
Short-term investments13529810050250  
Receivables21136012 
Inventory, net of allowances, customer advances and progress billings272728   
Inventory272728    
Prepaid expense4426341
Other current assets19987854
Other undisclosed current assets  20 (1)(2) 
Total current assets:366572627279540491329
Noncurrent Assets
Inventory, Noncurrent98114     
Property, plant and equipment152744531
Intangible assets, net (including goodwill)1261158578161279319
Goodwill63636557596675
Intangible assets, net (excluding goodwill)63522021102213245
Other noncurrent assets23232028131
Other undisclosed noncurrent assets4012     
Total noncurrent assets:30329110885174295321
TOTAL ASSETS:670864735365713786650
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities74964130231812
Accounts payable322915111134
Accrued liabilities426826191184
Employee-related liabilities     53
Taxes payable     0 
Interest and dividends payable     2 
Other undisclosed current liabilities5930403553309
Total current liabilities:1331268266764821
Noncurrent Liabilities
Long-term debt and lease obligation645575282281   
Long-term debt, excluding current maturities645575282281   
Liabilities, other than long-term debt, including:216415711975
Deferred revenue and credits411  
Deferred tax liabilities, net   316775
Other liabilities      0
Business combination, contingent consideration, liability    2552
Other undisclosed liabilities, other than long-term debt216     
Other undisclosed noncurrent liabilities64  2028028856
Total noncurrent liabilities:711591286303337407131
Total liabilities:844717368368413455152
Stockholders' equity
Stockholders' equity attributable to parent, including:(174)146368(4)301332498
Common stock0000000
Additional paid in capital2,1142,0341,8871,1751,130785762
Accumulated other comprehensive income (loss)(45)(45)(42)(48)(47)(24)5
Accumulated deficit(2,244)(1,843)(1,477)(1,131)(782)(429) 
Other undisclosed stockholders' equity attributable to parent      (269)
Total stockholders' equity:(174)146368(4)301332498
TOTAL LIABILITIES AND EQUITY:670864735365713786650

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues14395560   
Revenue, net560   
Cost of revenue
(Cost of Goods and Services Sold)
  (1)(0)   
Gross profit:14395540   
Operating expenses(520)(429)(293)(373)(377)(172)(84)
Other undisclosed operating income  10 14 
Operating loss:(377)(334)(238)(373)(377)(158)(84)
Nonoperating income (expense)(22)(34)(112)(8)(5)1(1)
Foreign currency transaction gain (loss), before tax(1)(0)(0)(1)34 
Other nonoperating income (expense)68410(0)(1)
Interest and debt expense18(3)(10)(8)(8)(3) 
Loss from continuing operations before equity method investments, income taxes:(380)(370)(360)(390)(390)(160)(84)
Other undisclosed income (loss) from continuing operations before income taxes(18)310883 
Loss from continuing operations before income taxes:(399)(367)(350)(381)(382)(158)(84)
Income tax expense (benefit)(2)(1)43229(2)(0)
Net loss available to common stockholders, diluted:(400)(368)(346)(349)(353)(160)(85)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(400)(368)(346)(349)(353)(160)(85)
Other comprehensive income (loss)(0)(2)5(0)(23)(29)5
Comprehensive loss, net of tax, attributable to parent:(401)(370)(341)(349)(376)(189)(80)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: